We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current LCTX market cap is 233.76M. The company's latest EPS is USD -0.1140 and P/E is -10.18.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 3M | 1.92M | 2.39M | 3.23M | 1.25M |
| Operating Income | -5.25M | -6.64M | -6.64M | -5.02M | -6.71M |
| Net Income | -6.07M | -6.35M | -4.37M | -5.23M | -7.11M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 3.52M | 1.83M | 4.34M | 14.7M | 8.95M |
| Operating Income | -38.88M | -26.45M | -49.21M | -22.52M | -24.73M |
| Net Income | -11.71M | -20.65M | -43.02M | -26.27M | -21.49M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 131.15M | 123.66M | 113.21M | 111.69M | 106.15M |
| Total Liabilities | 53.6M | 51.73M | 44.19M | 40.43M | 39.49M |
| Total Equity | 77.55M | 71.94M | 69.02M | 71.26M | 66.66M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 125.48M | 107.95M | 174.55M | 123.66M | 101.02M |
| Total Liabilities | 14.23M | 12.82M | 83.65M | 51.73M | 39M |
| Total Equity | 111.25M | 95.13M | 90.9M | 71.94M | 62.02M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 9.36M | 1.06M | -11.24M | -17.51M | -22.55M |
| Investing | -41.06M | -46.16M | 15.43M | 34.59M | 36.71M |
| Financing | 1.51M | 1.63M | 1,000 | 5.63M | 6.44M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -31.95M | -19.75M | -23.56M | 1.06M | -28.57M |
| Investing | 16.96M | 13.04M | 9.75M | -46.16M | 46.45M |
| Financing | 617k | 29.87M | 36.93M | 1.63M | 6.42M |
| Market Cap | 233.76M |
| Price to Earnings Ratio | -10.18 |
| Price to Sales Ratio | 24.47 |
| Price to Cash Ratio | 6.17 |
| Price to Book Ratio | 3.53 |
| Dividend Yield | - |
| Shares Outstanding | 188.53M |
| Average Volume (1 week) | 1.65M |
| Average Volume (1 Month) | 967.77k |
| 52 Week Change | -13.29% |
| 52 Week High | 1.61 |
| 52 Week Low | 0.8414 |
| Spread (Intraday) | 0.06 (4.84%) |
| Company Name | Lineage Cell Therapeutics Inc |
| Address |
2173 salk avenue alameda, california 92008 |
| Website | https://lineagecell.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
